We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+9.23%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$4.22B
AUM Growth
+$2.7B
Cap. Flow
+$3.76B
Cap. Flow %
89.24%
Top 10 Hldgs %
40.53%
Holding
623
New
593
Increased
5
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
OSH
Oak Street Health, Inc.
OSH
+$211M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$189M
3
UNVR
Univar Solutions Inc.
UNVR
+$175M
4
MAXR
Maxar Technologies Inc. Common Stock
MAXR
+$143M
5
AQUA
Evoqua Water Technologies Corp. Common Stock
AQUA
+$137M

Top Sells

Rank Stock Value
1
ATVI
Activision Blizzard
ATVI
+$196M
2
SGFY
Signify Health, Inc.
SGFY
+$161M
3
ONEM
1Life Healthcare
ONEM
+$141M
4
TGNA
TEGNA Inc
TGNA
+$46.6M

Sector Composition

Rank Sector Weight
1 Financials 22.21%
2 Healthcare 21.36%
3 Technology 18.59%
4 Industrials 5.57%
5 Real Estate 5.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDNW
401
RideNow Group
RDNW
$262M
$909K 0.02%
+150,000
New +$1.22M
DCPH
402
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$907K 0.02%
+58,695
New +$980K
LBPH
403
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$904K 0.02%
+230,000
New +$1.12M
EWTX icon
404
Edgewise Therapeutics
EWTX
$4.63B
$887K 0.02%
+132,968
New +$1.23M
ETNB
405
DELISTED
89bio
ETNB
$852K 0.02%
+55,939
New +$729K
INZY
406
DELISTED
Inozyme Pharma
INZY
$846K 0.02%
+147,654
New +$390K
NVNO
407
enVVeno Medical
NVNO
$6.78M
$840K 0.02%
+5,075
New +$949K
BHAC
408
DELISTED
Focus Impact BH3 Acquisition Company Class A Common Stock
BHAC
$835K 0.02%
+81,132
New +$828K
RZLT icon
409
Rezolute
RZLT
$443M
$827K 0.02%
+430,475
New +$969K
OSI
410
DELISTED
Osiris Acquisition Corp.
OSI
$808K 0.02%
+82,386
New +$821K
XRX icon
411
PUT
Xerox
XRX
$427M
$759K 0.02%
+248,800
New +$4.02M
GLUE icon
412
Monte Rosa Therapeutics
GLUE
$1.34B
$744K 0.02%
+95,528
New +$664K
RLAY icon
413
Relay Therapeutics
RLAY
$4.2B
$726K 0.02%
+44,100
New +$791K
F icon
414
PUT
Ford
F
$55.2B
$721K 0.02%
+771,200
New +$9.66M
PHAT icon
415
Phathom Pharmaceuticals
PHAT
$678M
$715K 0.02%
+100,093
New +$879K
REPL icon
416
Replimune Group
REPL
$1.02B
$698K 0.02%
+39,500
New +$939K
CRC icon
417
California Resources
CRC
$4.63B
$691K 0.02%
+17,959
New +$743K
DTIL icon
418
Precision BioSciences
DTIL
$208M
$691K 0.02%
+30,528
New +$1.01M
GEHC icon
419
GE HealthCare
GEHC
$32.2B
$689K 0.02%
+8,400
New +$600K
PEN icon
420
Penumbra
PEN
$12.8B
$681K 0.02%
+2,442
New +$623K
ACRS icon
421
Aclaris Therapeutics
ACRS
$851M
$677K 0.02%
+83,678
New +$1.06M
BCAB icon
422
BioAtla
BCAB
$5.63M
$657K 0.02%
+4,901
New +$883K
BAX icon
423
Baxter International
BAX
$14.1B
$653K 0.02%
+16,097
New +$682K
RVNC
424
DELISTED
Revance Therapeutics, Inc.
RVNC
$651K 0.02%
+20,214
New +$630K
ANNX icon
425
Annexon
ANNX
$901M
$643K 0.02%
+166,907
New +$918K
15 16
17
18 19

Similar funds

FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
SAG
SageView Advisory Group Newport Beach, California $2.96B AUM 15.81% 1-Year Est. Return
ACI
Alpha Cubed Investments Irvine, California $2.92B AUM 31.27% 1-Year Est. Return
TCOV
Trust Company of Vermont Brattleboro, Vermont $2.4B AUM 18.8% 1-Year Est. Return
RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
A
AlphaQuest New York $1.79B AUM 10.61% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
CB
Cadence Bank Tupelo, Mississippi $1.71B AUM 16.17% 1-Year Est. Return

UBS O'Connor's Q1 2023 Portfolio in Review

As of Q1 2023, UBS O'Connor held 623 positions worth $4.22B, up 177% from $1.52B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

UBS O'Connor deployed $3.76B of net new capital in Q1 2023, opening 593 new positions and adding to 5 existing holdings. Its largest new stake was Oak Street Health, Inc.: 6,537,297 shares worth $25.3M.

By sector, the portfolio is most concentrated in Financials at 22% of assets, up from 14% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Activision Blizzard, an estimated $196M trimmed.

  • UBS O'Connor's largest Q1 2023 buy was Oak Street Health, Inc.: 6,537,297 shares worth $25.3M.
  • UBS O'Connor added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2023, an estimated $189M increase.
  • UBS O'Connor's biggest Q1 2023 reduction was Activision Blizzard, cutting an estimated $196M.
  • UBS O'Connor fully exited Signify Health, Inc. in Q1 2023, selling an estimated $161M.
  • UBS O'Connor's ten largest holdings make up 41% of its $4.22B portfolio in Q1 2023.
  • UBS O'Connor opened 593 new positions and closed 3 in Q1 2023.
  • UBS O'Connor's portfolio value rose 177% quarter-over-quarter to $4.22B.

Based on UBS O'Connor's 13F filing for Q1 2023, filed 15 May 2023.